Study of arrhythmia prevalence in NUVANT Mobile Cardiac Telemetry system patients.
The Corventis NUVANT™ Mobile Cardiac Telemetry system is an innovative solution in the field of continuous monitoring of symptomatic and asymptomatic cardiac abnormalities to help physicians diagnose and treat non-lethal cardiac arrhythmias. As an FDA cleared product on the market for more than 2 years, the collected body of patient data represents a unique and powerful source of clinical information. Analysis of a sample of 951 NUVANT patients has revealed interesting statistics on the prevalence of various cardiac arrhythmias in the patient population. The population is non-randomized and largely consists of US patients where a traditional Holter Monitor study was negative. The analysis here is focused on classifying the detected arrhythmias using potential therapy solutions as a classifier. Across the total population, 2.2% of patients presented arrhythmias indicating assessment for clinically significant tachycardia, 19% indications of potential bradycardia, 20% had indications of atrial fibrillation, 1% indicating arrhythmias requiring other conditional treatment, and 58% presenting arrhythmias likely not requiring treatment.
Corventis, Inc, Saint Paul, MN 55108, USA. jonathan.engel@corventis.com
Jonathan M
JM
Engel
Vipin
V
Mehta
Richard
R
Fogoros
Abhi
A
Chavan
D000328:Adult; D000368:Aged; D001145:Arrhythmias, Cardiac / Q000453:epidemiology*; D001281:Atrial Fibrillation / Q000453:epidemiology; D001919:Bradycardia / Q000453:epidemiology; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D015995:Prevalence; D013610:Tachycardia / Q000453:epidemiology; D013686:Telemetry